The recent MultiPoint™ Pacing U.S. IDE study from Tomassoni et al. showed:
The sub-analysis study demonstrated that wider cathode spacing and near-simultaneous intraventricular timing delays are best. When MultiPoint™ Pacing technology was programmed with cathode spacing ≥ 30 mm and 5 ms LV delay:
Conclusions from the U.S. IDE study include:
Several international studies report results related to improved patient response to CRT with MultiPoint Pacing as compared to single-site pacing.
Zanon et al. compared 20 patients optimized with MultiPoint Pacing to 36 patients optimized with traditional BiV pacing and 54 nonoptimized BiV patients.2 The results indicate a progression in response from nonoptimized BiV to optimized BiV to optimized with MultiPoint Pacing at 12 months consistently measured over three definitions of response:
Forleo et al. compared the changes in ejection fraction (EF) in 232 patients with a 6-month follow-up.3 During implant, capture thresholds were measured as well as the presence of PNS. The results show:
In summary, the Italian MPP technology registry (IRON-MPP) study showed QRS was reduced and both EF and clinical composite score improved with MPP technology relative to conventional BiV.³
The Quadra Allure MP™ CRT-P Is one of our heart failure management therapies. Our vision is to transform the treatment of heart failure by designing technology that delivers excellent clinical outcomes and improves workflow and efficiency. Read more about our approach to heart failure management.